Skip to main
BWAY

Brainsway (BWAY) Stock Forecast & Price Target

Brainsway (BWAY) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrainsWay is a highly promising medical technology company that offers advanced non-invasive treatments for mental health disorders through its Deep TMS platform. With a profitable recurring revenue model and investments in expanding their reach, the company is well-positioned in the TMS market and is also venturing into new treatment options like psilocybin therapy. Although facing competition and execution risks, their strong financials and track record make them a promising investment for the future.

Bears say

BrainsWay is in a growing market with a well-defined customer base and recurring revenue model, but its long-term growth is dependent on execution of clinical trials and reimbursement for novel indications. Despite its strong position in the US market, the company faces significant risks, including delays in clinical trials, failure to expand reimbursement, and potential dilution. These risks, coupled with a projected sales multiple-driven valuation of $17 per share, make the current stock outlook negative for financial analysts.

Brainsway (BWAY) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Brainsway (BWAY) Forecast

Analysts have given Brainsway (BWAY) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Brainsway (BWAY) has a Strong Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Brainsway (BWAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.